- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT05156281
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)
Une étude randomisée, en double aveugle, double factice, en groupes parallèles, comparant l'efficacité et l'innocuité du remibrutinib par rapport au tériflunomide chez des participants atteints de sclérose en plaques récurrente, suivie d'un traitement prolongé avec le remibrutinib en ouvert
To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
The study CLOU064C12302 consists of an initial Core Part (CP) (maximum duration per participant of up to 30 months), followed by an Extension Part (EP, of up to 5 years duration) for eligible participants.
The Core Part is a randomized, double-blind, double-dummy, active comparator-controlled, fixed-dose, parallel-group, multi-center study in approximately 800 participants with relapsing multiple sclerosis (RMS).
The Extension Part is an open-label, single-arm, fixed-dose design in which eligible participants are treated with remibrutinib for up to 5 years.
A second study of identical design (CLOU064C12301) will be conducted simultaneously. Both studies will be conducted globally and data from the two studies will be pooled for some of the endpoints.
Type d'étude
Inscription (Réel)
Phase
- Phase 3
Contacts et emplacements
Lieux d'étude
-
-
-
Pretoria, Afrique du Sud, 0041
- Novartis Investigative Site
-
Rosebank, Afrique du Sud, 2196
- Novartis Investigative Site
-
-
Free State
-
Bloemfontein, Free State, Afrique du Sud, 9301
- Novartis Investigative Site
-
-
-
-
-
Essen, Allemagne, 45147
- Novartis Investigative Site
-
Hamburg, Allemagne, 22179
- Novartis Investigative Site
-
-
Baden-Wurttemberg
-
Freiburg im Breisgau, Baden-Wurttemberg, Allemagne, 79106
- Novartis Investigative Site
-
-
-
-
-
Buenos Aires, Argentine, C1012AAR
- Novartis Investigative Site
-
CABA, Argentine, C1181ACH
- Novartis Investigative Site
-
Córdoba, Argentine, X5004CDT
- Novartis Investigative Site
-
-
Mendoza Province
-
Bombal, Mendoza Province, Argentine, M5500DXO
- Novartis Investigative Site
-
-
Santa Fe Province
-
Rosario, Santa Fe Province, Argentine, S2000BZL
- Novartis Investigative Site
-
Rosario, Santa Fe Province, Argentine, S2000DSW
- Novartis Investigative Site
-
-
Tucumán Province
-
San Miguel de, Tucumán Province, Argentine, T4000
- Novartis Investigative Site
-
-
-
-
-
São Paulo, Brésil, 01240-020
- Novartis Investigative Site
-
-
Espírito Santo
-
Vitória, Espírito Santo, Brésil, 29055-450
- Novartis Investigative Site
-
-
Federal District
-
Brasília, Federal District, Brésil, 70200-730
- Novartis Investigative Site
-
-
Paraná
-
Curitiba, Paraná, Brésil, 81210-310
- Novartis Investigative Site
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brésil, 90430-001
- Novartis Investigative Site
-
Porto Alegre, Rio Grande do Sul, Brésil, 90560-032
- Novartis Investigative Site
-
Porto Alegre, Rio Grande do Sul, Brésil, 90620-130
- Novartis Investigative Site
-
-
Santa Catarina
-
Joinville, Santa Catarina, Brésil, 89202-165
- Novartis Investigative Site
-
-
-
-
-
Plovdiv, Bulgarie, 4002
- Novartis Investigative Site
-
Sofia, Bulgarie, 1309
- Novartis Investigative Site
-
Sofia, Bulgarie, 1431
- Novartis Investigative Site
-
Sofia, Bulgarie, 1407
- Novartis Investigative Site
-
-
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 2B7
- Novartis Investigative Site
-
-
British Columbia
-
Burnaby, British Columbia, Canada, V5G 2X6
- Novartis Investigative Site
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H 4K4
- Novartis Investigative Site
-
-
Ontario
-
Ottawa, Ontario, Canada, K1H 8L6
- Novartis Investigative Site
-
-
Quebec
-
Lévis, Quebec, Canada, G6W 0M5
- Novartis Investigative Site
-
Montreal, Quebec, Canada, H4A 3T2
- Novartis Investigative Site
-
Québec, Quebec, Canada, G1J 1Z4
- Novartis Investigative Site
-
Saint-Jérôme, Quebec, Canada, J7Z 5T3
- Novartis Investigative Site
-
-
-
-
-
Beijing, Chine, 100034
- Novartis Investigative Site
-
Shanghai, Chine, 200025
- Novartis Investigative Site
-
Shanghai, Chine, 200040
- Novartis Investigative Site
-
-
Hubei
-
Wuhan, Hubei, Chine, 430030
- Novartis Investigative Site
-
Wuhan, Hubei, Chine, 430060
- Novartis Investigative Site
-
-
Jiangsu
-
Nanjing, Jiangsu, Chine, 210029
- Novartis Investigative Site
-
-
Ningxia
-
Yinchuan, Ningxia, Chine, 750004
- Novartis Investigative Site
-
-
Shanxi
-
Taiyuan, Shanxi, Chine, 030001
- Novartis Investigative Site
-
-
Zhejiang
-
Hangzhou, Zhejiang, Chine, 310016
- Novartis Investigative Site
-
Hangzhou, Zhejiang, Chine, 310006
- Novartis Investigative Site
-
Wenzhou, Zhejiang, Chine, 325000
- Novartis Investigative Site
-
-
-
-
-
Zagreb, Croatie, 10000
- Novartis Investigative Site
-
-
Croatia
-
Zagreb, Croatia, Croatie, 10000
- Novartis Investigative Site
-
-
HRV
-
Split, HRV, Croatie, 21000
- Novartis Investigative Site
-
Varaždin, HRV, Croatie, 42000
- Novartis Investigative Site
-
-
Vukovar
-
Vukovar, Vukovar, Croatie, 32000
- Novartis Investigative Site
-
-
-
-
-
Lleida, Espagne, 25198
- Novartis Investigative Site
-
Madrid, Espagne, 28040
- Novartis Investigative Site
-
Madrid, Espagne, 28009
- Novartis Investigative Site
-
Málaga, Espagne, 29016
- Novartis Investigative Site
-
Seville, Espagne, 41009
- Novartis Investigative Site
-
Valencia, Espagne, 46026
- Novartis Investigative Site
-
-
A Coruna
-
Santiago Compostela, A Coruna, Espagne, 15706
- Novartis Investigative Site
-
-
Araba
-
Vitoria-Gasteiz, Araba, Espagne, 01009
- Novartis Investigative Site
-
-
Barcelona
-
L'Hospitalet de Llobregat, Barcelona, Espagne, 08907
- Novartis Investigative Site
-
-
Castille-La Mancha
-
Albacete, Castille-La Mancha, Espagne, 02006
- Novartis Investigative Site
-
-
Catalonia
-
Barcelona, Catalonia, Espagne, 08003
- Novartis Investigative Site
-
-
La Rioja
-
Logroño, La Rioja, Espagne, 26006
- Novartis Investigative Site
-
-
Madrid
-
Pozuelo de Alarcón, Madrid, Espagne, 28223
- Novartis Investigative Site
-
Torrejón de Ardoz, Madrid, Espagne, 28850
- Novartis Investigative Site
-
-
Principality of Asturias
-
Gijón, Principality of Asturias, Espagne, 33394
- Novartis Investigative Site
-
-
Valencia
-
Valencia, Valencia, Espagne, 46017
- Novartis Investigative Site
-
-
-
-
-
Tallinn, Estonie, 11315
- Novartis Investigative Site
-
Tartu, Estonie, 50406
- Novartis Investigative Site
-
-
-
-
-
Caen, France, 14033
- Novartis Investigative Site
-
Clermont-Ferrand, France, 63003
- Novartis Investigative Site
-
Dijon, France, 21000
- Novartis Investigative Site
-
Gonesse, France, 95500
- Novartis Investigative Site
-
Grenoble, France, 38043
- Novartis Investigative Site
-
Lille, France, 59037
- Novartis Investigative Site
-
Lille, France, 59000
- Novartis Investigative Site
-
Nice, France, 06000
- Novartis Investigative Site
-
Nîmes, France, 30029
- Novartis Investigative Site
-
Poissy, France, 78303
- Novartis Investigative Site
-
Toulouse, France, 31059
- Novartis Investigative Site
-
-
Haute Vienne
-
Limoges, Haute Vienne, France, 87000
- Novartis Investigative Site
-
-
Val De Marne
-
Toulon, Val De Marne, France, 83800
- Novartis Investigative Site
-
-
-
-
-
Athens, Grèce, 115 28
- Novartis Investigative Site
-
Athens, Grèce, 115 26
- Novartis Investigative Site
-
Chaïdári, Grèce, 124 62
- Novartis Investigative Site
-
Ioannina, Grèce, 455 00
- Novartis Investigative Site
-
Larissa, Grèce, 411 10
- Novartis Investigative Site
-
Thessaloniki, Grèce, 532 46
- Novartis Investigative Site
-
Thessaloniki, Grèce, 546 36
- Novartis Investigative Site
-
-
-
-
Kerala
-
Kochi, Kerala, Inde, 682025
- Novartis Investigative Site
-
-
Maharashtra
-
Pune, Maharashtra, Inde, 411013
- Novartis Investigative Site
-
-
National Capital Territory of Delhi
-
New Delhi, National Capital Territory of Delhi, Inde, 110060
- Novartis Investigative Site
-
-
Punjab
-
Amritsar, Punjab, Inde, 143006
- Novartis Investigative Site
-
-
Telangana
-
Hyderabad, Telangana, Inde, 500082
- Novartis Investigative Site
-
-
Uttar Pradesh
-
Lucknow, Uttar Pradesh, Inde, 226007
- Novartis Investigative Site
-
-
West Bengal
-
Kolkata, West Bengal, Inde, 700017
- Novartis Investigative Site
-
-
-
-
-
Naples, Italie, 80138
- Novartis Investigative Site
-
-
BR
-
Brindisi, BR, Italie, 72100
- Novartis Investigative Site
-
-
FG
-
Foggia, FG, Italie, 71122
- Novartis Investigative Site
-
-
IS
-
Pozzilli, IS, Italie, 86077
- Novartis Investigative Site
-
-
ME
-
Messina, ME, Italie, 98124
- Novartis Investigative Site
-
-
MO
-
Modena, MO, Italie, 41126
- Novartis Investigative Site
-
-
PV
-
Pavia, PV, Italie, 27100
- Novartis Investigative Site
-
-
TO
-
Orbassano, TO, Italie, 10043
- Novartis Investigative Site
-
-
-
-
-
Fukuoka, Japon, 8128582
- Novartis Investigative Site
-
Niigata, Japon, 9518520
- Novartis Investigative Site
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Japon, 4668560
- Novartis Investigative Site
-
-
Chiba
-
Chiba, Chiba, Japon, 2608677
- Novartis Investigative Site
-
Ichihara, Chiba, Japon, 2990111
- Novartis Investigative Site
-
-
Fukuoka
-
Fukuoka, Fukuoka, Japon, 8100022
- Novartis Investigative Site
-
-
Hokkaido
-
Sapporo, Hokkaido, Japon, 0630005
- Novartis Investigative Site
-
-
Hyōgo
-
Kobe, Hyōgo, Japon, 6500017
- Novartis Investigative Site
-
Nishinomiya, Hyōgo, Japon, 663 8501
- Novartis Investigative Site
-
-
Kanagawa
-
Isehara, Kanagawa, Japon, 2591193
- Novartis Investigative Site
-
Sagamihara, Kanagawa, Japon, 2520375
- Novartis Investigative Site
-
-
Kyoto
-
Kyoto, Kyoto, Japon, 6168255
- Novartis Investigative Site
-
-
Miyagi
-
Sendai, Miyagi, Japon, 9838512
- Novartis Investigative Site
-
-
Nara
-
Kashihara, Nara, Japon, 6348522
- Novartis Investigative Site
-
-
Osaka
-
Moriguchi, Osaka, Japon, 5708507
- Novartis Investigative Site
-
Suita, Osaka, Japon, 5650871
- Novartis Investigative Site
-
-
Saitama
-
Higashi-Matsuyama, Saitama, Japon, 3550005
- Novartis Investigative Site
-
-
Tokyo
-
Kodaira, Tokyo, Japon, 1878551
- Novartis Investigative Site
-
Shinjuku Ku, Tokyo, Japon, 1628666
- Novartis Investigative Site
-
Shinjuku Ku, Tokyo, Japon, 1600023
- Novartis Investigative Site
-
Shinjuku-ku, Tokyo, Japon, 1608582
- Novartis Investigative Site
-
tabashi City, Tokyo, Japon, 1738610
- Novartis Investigative Site
-
-
-
-
-
Braga, Le Portugal, 4710-243
- Novartis Investigative Site
-
Coimbra, Le Portugal, 3004-561
- Novartis Investigative Site
-
Leiria, Le Portugal, 2410-197
- Novartis Investigative Site
-
Lisbon, Le Portugal, 1649-035
- Novartis Investigative Site
-
Lisbon, Le Portugal, 1169-050
- Novartis Investigative Site
-
Matosinhos Municipality, Le Portugal, 4454-513
- Novartis Investigative Site
-
Santa Maria da Feira, Le Portugal, 4520-211
- Novartis Investigative Site
-
-
-
-
-
Mexico City, Mexique, 14050
- Novartis Investigative Site
-
Querétaro, Mexique, 76070
- Novartis Investigative Site
-
-
Chihuahua
-
Chihuahua City, Chihuahua, Mexique, 31203
- Novartis Investigative Site
-
-
Mexico City
-
Mexico City, Mexico City, Mexique, 06700
- Novartis Investigative Site
-
-
-
-
-
Bialystok, Pologne, 15-704
- Novartis Investigative Site
-
Glogow Wielkopolski, Pologne, 36-060
- Novartis Investigative Site
-
Katowice, Pologne, 40-081
- Novartis Investigative Site
-
Katowice, Pologne, 40-571
- Novartis Investigative Site
-
Katowice, Pologne, 40-686
- Novartis Investigative Site
-
Katowice, Pologne, 40-689
- Novartis Investigative Site
-
Lublin, Pologne, 20-701
- Novartis Investigative Site
-
Wroclaw, Pologne, 51-685
- Novartis Investigative Site
-
Zabrze, Pologne, 41-800
- Novartis Investigative Site
-
-
Poznan
-
Plewiska, Poznan, Pologne, 62-064
- Novartis Investigative Site
-
-
-
-
-
Guaynabo, Porto Rico, 00968
- Caribbean Center for Clinical Research Inc
-
-
-
-
-
Campulung Muscel, Roumanie, 115100
- Novartis Investigative Site
-
Constanța, Roumanie, 900591
- Novartis Investigative Site
-
-
ROM
-
Brasov, ROM, Roumanie, 500123
- Novartis Investigative Site
-
Constanța, ROM, Roumanie, 900123
- Novartis Investigative Site
-
-
-
-
Invernesshire
-
Inverness, Invernesshire, Royaume-Uni, IV2 3RE
- Novartis Investigative Site
-
-
Kent
-
Canterbury, Kent, Royaume-Uni, CT1 3NG
- Novartis Investigative Site
-
-
-
-
-
Banská Bystrica, Slovaquie, 975 17
- Novartis Investigative Site
-
Banská Bystrica, Slovaquie, 974 04
- Novartis Investigative Site
-
Bratislava, Slovaquie, 833 05
- Novartis Investigative Site
-
-
-
-
-
Celje, Slovénie, 3000
- Novartis Investigative Site
-
Ljubljana, Slovénie, 1000
- Novartis Investigative Site
-
-
Slovenia
-
Maribor, Slovenia, Slovénie, 2000
- Novartis Investigative Site
-
-
-
-
-
Stockholm, Suède, 102 35
- Novartis Investigative Site
-
-
-
-
-
Brno, Tchéquie, 602 00
- Novartis Investigative Site
-
Hradec Králové, Tchéquie, 500 05
- Novartis Investigative Site
-
Teplice, Tchéquie, 415 29
- Novartis Investigative Site
-
-
-
-
-
Konya, Turquie (Türkiye), 42130
- Novartis Investigative Site
-
-
Atakum
-
Samsun, Atakum, Turquie (Türkiye), 55200
- Novartis Investigative Site
-
-
Balcova
-
Izmir, Balcova, Turquie (Türkiye), 35340
- Novartis Investigative Site
-
-
Fatih
-
Istanbul, Fatih, Turquie (Türkiye), 34098
- Novartis Investigative Site
-
Istanbul, Fatih, Turquie (Türkiye), 34093
- Novartis Investigative Site
-
-
Karabaglar
-
Izmir, Karabaglar, Turquie (Türkiye), 35150
- Novartis Investigative Site
-
-
Kocaeli
-
Köseköy, Kocaeli, Turquie (Türkiye), 41380
- Novartis Investigative Site
-
-
Melikgazi
-
Kayseri, Melikgazi, Turquie (Türkiye), 38039
- Novartis Investigative Site
-
-
Nilufer
-
Bursa, Nilufer, Turquie (Türkiye), 16140
- Novartis Investigative Site
-
-
Pendik
-
Istanbul, Pendik, Turquie (Türkiye), 34899
- Novartis Investigative Site
-
-
Sancaktepe
-
Istanbul, Sancaktepe, Turquie (Türkiye), 34785
- Novartis Investigative Site
-
-
-
-
Arizona
-
Phoenix, Arizona, États-Unis, 85018
- Ctr for Neurology and Spine
-
-
California
-
Hanford, California, États-Unis, 93230
- Vladimir Royter MD APMC
-
Los Angeles, California, États-Unis, 90073
- VA Greater LA Healthcare System
-
West Hollywood, California, États-Unis, 90048
- Regina Berkovich MD PhD Inc
-
-
Colorado
-
Aurora, Colorado, États-Unis, 80045
- CU Anschutz Med Campus
-
Denver, Colorado, États-Unis, 80210
- Colorado Neurological Research PC
-
-
Connecticut
-
Stamford, Connecticut, États-Unis, 06905
- New England Institute for Clinical Research
-
-
District of Columbia
-
Washington D.C., District of Columbia, États-Unis, 20007
- Georgetown University Hospital
-
Washington D.C., District of Columbia, États-Unis, 20007
- Georgetown University Hospital Research
-
-
Florida
-
Bradenton, Florida, États-Unis, 34209
- Nova Clinical Research LLC
-
Gainesville, Florida, États-Unis, 32610
- University of Florida
-
Hollywood, Florida, États-Unis, 33021
- Memorial Healthcare System
-
Maitland, Florida, États-Unis, 32751
- Neurology Associates PA
-
Miami, Florida, États-Unis, 33136
- UM Department Of Neurology
-
Miami, Florida, États-Unis, 33133
- Gables Neurology
-
Naples, Florida, États-Unis, 34105
- Aqualane Clinical Research
-
Orlando, Florida, États-Unis, 32803
- Advent Health Orlando
-
Pembroke Pines, Florida, États-Unis, 33024
- Humanity Clinical Research
-
Pensacola, Florida, États-Unis, 32514
- Emerald Coast Neurology
-
Port Orange, Florida, États-Unis, 32127
- Brain and Spine Institute
-
Vero Beach, Florida, États-Unis, 32960
- Vero Beach Neurology
-
Winter Park, Florida, États-Unis, 32789
- Conquest Research
-
-
Indiana
-
Merrillville, Indiana, États-Unis, 46410
- Methodist Neuroscience Institute
-
-
Kansas
-
Kansas City, Kansas, États-Unis, 66160
- University of Kansas Hospital
-
-
Kentucky
-
Nicholasville, Kentucky, États-Unis, 40356
- Baptist Physicians Lexington
-
-
Louisiana
-
New Orleans, Louisiana, États-Unis, 70121
- Ochsner Clinic Foundation
-
-
Maryland
-
Frederick, Maryland, États-Unis, 21702
- Clinre Comprehensive Neurology
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02111
- Tufts Medical Center
-
-
Missouri
-
Kansas City, Missouri, États-Unis, 64128
- Kansas City VA Medical Center
-
-
New York
-
Patchogue, New York, États-Unis, 11772
- South Shore Neurologic Associates
-
-
North Carolina
-
Chapel Hill, North Carolina, États-Unis, 27599-9500
- University Of NC At Chapel Hill
-
Charlotte, North Carolina, États-Unis, 28210
- Piedmont HealthCare
-
-
Ohio
-
Columbus, Ohio, États-Unis, 43235
- The Boster Ctr for MS
-
Dayton, Ohio, États-Unis, 45408
- Neurology Diagnostics Inc
-
-
Pennsylvania
-
Hershey, Pennsylvania, États-Unis, 17033
- Penn State Hershey Medical Center
-
-
South Carolina
-
Greenville, South Carolina, États-Unis, 29605
- Premier Neurology
-
Old Point Station, South Carolina, États-Unis, 29707
- Metrolina Neurological Associates PA
-
-
Tennessee
-
Knoxville, Tennessee, États-Unis, 37922
- Sibyl Wray MD Neurology PC
-
-
Texas
-
Dallas, Texas, États-Unis, 75231
- Carum Research
-
El Paso, Texas, États-Unis, 79935
- Med Research Inc
-
Frisco, Texas, États-Unis, 75035
- Lone Star Neurology
-
San Antonio, Texas, États-Unis, 78258
- Lonestar Neurology of San Antonio
-
San Antonio, Texas, États-Unis, 78229
- UT Health MARC Medical Arts and Research Center
-
Sherman, Texas, États-Unis, 75092
- Texas Institute for Neurological Disorders
-
Temple, Texas, États-Unis, 76508
- Baylor Scott and White
-
-
Washington
-
Seattle, Washington, États-Unis, 98101
- Virginia Mason Medical Centre
-
Seattle, Washington, États-Unis, 98133
- University of Washington MS Clinic
-
-
West Virginia
-
Crab Orchard, West Virginia, États-Unis, 25827
- Elligo Health Research
-
-
Wisconsin
-
Milwaukee, Wisconsin, États-Unis, 53226
- Medical College of Wisconsin
-
Milwaukee, Wisconsin, États-Unis, 53215
- Ascension St Francis Center
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- 18 to 55 years of age
- Diagnosis of RMS according to the 2017 McDonald diagnostic criteria
- At least: 1 documented relapse within the previous year. OR 2 documented relapses within the previous 2 years, OR 1 active Gadolinium (Gd)-enhancing lesion in the 12 months.
- EDSS score of 0 to 5.5 (inclusive)
- Neurologically stable within 1 month
Exclusion Criteria:
-
Diagnosis of primary progressive multiple sclerosis (PPMS)
-
Disease duration of more than 10 years in participants with EDSS score of 2 or less at screening
-
History of clinically significant CNS disease other than MS
-
Ongoing substance abuse (drug or alcohol)
-
History of malignancy of any organ system (other than complete resection of localized basal cell carcinoma of the skin or in situ cervical cancer),
-
Participants with history of confirmed Progressive Multifocal Leukoencephalopathy (PML) or Neurological symptoms consistent with PML
-
suicidal ideation or behavior
-
Evidence of clinically significant cardiovascular, neurological, psychiatric, pulmonary , renal, hepatic, endocrine, metabolic, hematological disorders or gastrointestinal disease that can interfere with interpretation of the study results or protocol adherence
-
Participants who have had a splenectomy
-
Active clinically significant systemic bacterial, viral, parasitic or fungal infections
-
Positive results for syphilis or tuberculosis testing
-
Uncontrolled disease states, such as asthma, or inflammatory bowel disease, where flares are commonly treated with oral or parenteral corticosteroids
-
Active, chronic disease of the immune system (including stable disease treated with immune therapy (e.g. Leflunomide, Methotrexate)) other than MS (e.g. rheumatoid arthritis, systemic lupus erythematosus, etc.) with the exception of well-controlled diabetes or thyroid disorder.
-
Participants with a known immunodeficiency syndrome (AIDS, hereditary immune deficiency, drug induced immune deficiency), or tested positive for HIV antibody
-
History or current treatment for hepatic disease including but not limited to acute or chronic hepatitis, cirrhosis (including all Child-Pugh classes) or hepatic failure or any chronic liver or biliary disease.
-
History of severe renal disease or creatinine level
-
Participants at risk of developing or having reactivation of hepatitis
-
Hematology parameters at screening:
- Hemoglobin: < 10 g/dl (<100g/L)
- Platelets: < 100000/mm3 (<100 x 109/L)
- Absolute lymphocyte count < 800/mm3 (<0.8 x 109/L)
- White blood cells: <3 000/mm3 (<3.0 x 109/L)
- Neutrophils: < 1 500/mm3 (<1.5 x 109/L)
- B-cell count < 50% lower limit of normal (LLN) or total IgG & total IgM < LLN (only required for participants who had a history of receiving B-cell therapies, such as rituximab, ocrelizumab or ofatumumab, prior to screening)
-
History or current diagnosis of significant ECG abnormalities
-
Resting QTcF ≥450 msec (male) or ≥460 msec (female) at pre-treatment as per central ECG reading at screening visit
-
Use of other investigational drugs
-
Requirement for anticoagulant medication or use of dual anti-platelet therapy Significant bleeding risk or coagulation disorders,
-
History of gastrointestinal bleeding
-
Major surgery within 8 weeks prior to screening
-
History of hypersensitivity to any of the study drugs or excipients
-
Pregnant or nursing (lactating) female participants, prior to randomization
-
Women of childbearing potential not using highly effective contraception
-
Sexually active males not agreeing to use condom
-
Have received any live or live-attenuated vaccines within 6 weeks of randomization or requirement to receive these vaccinations during study
-
Use of strong CYP3A4 inhibitors or use of moderate or strong CYP3A4 inducers within two weeks prior to randomization
Inclusion to Extension part:
• Participants who complete the Core Part of the study on double-blind study treatment and conduct the Accelerated Elimination Procedure (AEP)
Other inclusion and exclusion criteria may apply.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Remibrutinib - Core
Remibrutinib tablet and matching placebo of teriflunomide capsule |
tablet taken orally
Autres noms:
|
|
Comparateur actif: Teriflunomide - Core
Teriflunomide capsule and matching placebo remibrutinib tablet |
capsule taken orally |
|
Expérimental: Remibrutinib - Extension
Participants on remibrutinib in Core will continue on remibrutinib tablet |
tablet taken orally
Autres noms:
|
|
Expérimental: Remibrutinib - Extension (on teriflunomide in Core)
Participants on teriflunomide in Core will switch to remibrutinib tablet |
tablet taken orally
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Annualized relapse rate (ARR) of confirmed relapses [Core Part]
Délai: From Baseline, up to 30 months
|
ARR is the average number of confirmed MS relapses in a year |
From Baseline, up to 30 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Time to 3-month confirmed disability progression (3mCDP) on Expanded Disability Status Scale (EDSS) [Core Part] (pooled data)
Délai: Baseline up to 30 months
|
Time to 3-month confirmed disability progression (3mCDP) is defined as an increase in Expanded Disability Status Scale (EDSS) which is sustained for at least 3 months |
Baseline up to 30 months
|
|
Time to 6-month confirmed disability progression (6mCDP) on EDSS [Core Part] (pooled data)
Délai: Baseline up to 30 months
|
Time to 6-month confirmed disability progression (6mCDP) is defined as an increase in Expanded Disability Status Scale (EDSS) which is sustained for at least 6 months |
Baseline up to 30 months
|
|
Annualized rate of new or enlarging T2 lesion [Core Part]
Délai: Baseline up to 30 months
|
Number of new/newly enlarged T2 lesions per year |
Baseline up to 30 months
|
|
Neurofilament light chain (Nfl) [Core Part]
Délai: Baseline up to 30 months
|
Neurofilament light chain (NfL) concentration in serum |
Baseline up to 30 months
|
|
Number of Gd-enhancing T1 lesions per MRI scan [Core Part]
Délai: Baseline up to 30 months
|
Average number of Gd-enhancing T1 lesions per scan |
Baseline up to 30 months
|
|
Percentage of participants with No Evidence of Disease Activity-3 (NEDA-3) [Core Part] (pooled data)
Délai: Baseline up to 30 months
|
Percentage of participants with No Evidence of Disease Activity-3 (NEDA-3), as assessed by absence of confirmed MS relapses, 6mCDP and new/enlarging T2 lesions on MRI |
Baseline up to 30 months
|
|
Time to first confirmed relapse [Core Part]
Délai: Baseline up to 30 months
|
Change in the Expanded Disability Status Scale (EDSS), an increase of at least 0.5 points on the EDSS (total) score, or an increase of at least 1 point on at least two functional scores (FSs), or an increase of at least 2 points on at least one FS, excluding changes involving bowel/bladder or cerebral FS, compared to the previous available rating. |
Baseline up to 30 months
|
|
Time to 6-month confirmed disability improvement (6mCDI) on EDSS [Core Part] (pooled data)
Délai: Baseline up to 30 months
|
Decrease in Expanded Disability Status Scale Score (EDSS) which is sustained for at least 6 months |
Baseline up to 30 months
|
|
Time to 3-months confirmed disability progression (3mCDP) and 6-month confirmed disability progression (6mCDP) independent of relapse activity (PIRA) [Core Part] (pooled data)
Délai: Baseline up to 30 months
|
Time to 3-month confirmed disability progression (3mCDP) and 6-month confirmed disability progression (6mCDP) is defined as an increase in Expanded Disability Status Scale (EDSS) which is sustained for at least 3 months or 6 months, respectively, without an on-study relapse before or on the day of a progression eve |
Baseline up to 30 months
|
|
Change from baseline in the Symbol Digit Modalities Test (SDMT) [Core Part] (pooled data)
Délai: Baseline up to 30 months
|
Symbol Digit Modalities Test (SDMT), an array of symbols paired with empty spaces, measures processing in speed; participants verbally match the number for each symbol as rapidly as possible. The score is the number of correctly coded items in 90 seconds. Higher scores indicate improvement. Lower scores indicate worsening |
Baseline up to 30 months
|
|
Time to 6-month confirmed worsening by at least 20% in the Timed 25-foot walk test (T25FW) [Core Part] (pooled data)
Délai: Baseline, up to 30 months
|
The patient walking speed to cover 25-foot distance is recorded in seconds. Longer time indicates poorer lower limb function. 20% worsening is defined as 20% increase from baseline T25FW score |
Baseline, up to 30 months
|
|
Time to 6-month confirmed worsening by at least 20% in the Timed 9-hole peg test (9HPT) (pooled data) [Core Part] (pooled data)
Délai: Baseline up to 30 months
|
The patient's right and left arm function to peg 9 holes measured in seconds. Longer time indicates poorer upper limb function. 20% worsening is defined as 20% increase from baseline 9HPT score in at least one hand (average of two trials per hand) |
Baseline up to 30 months
|
|
Time to composite 6-month confirmed disability Progression (CDP) [Core Part] (pooled data)
Délai: Baseline up to 30 months
|
The composite involves CDP and worsening by at least 20% in T25FW and 9HPT |
Baseline up to 30 months
|
|
Change from Baseline in T2 lesion volume [Core Part]
Délai: Baseline up to 30 months
|
Change from baseline in total T2 lesion volume. |
Baseline up to 30 months
|
|
Change from baseline in Multiple Sclerosis Impact Scale (MSIS-29) [Core Part]
Délai: Baseline up to 30 months
|
29-item, self-administered questionnaire that includes 2 domains, physical and psychological. Responses are captured on a 4-point scale ranging from "not at all" (1) to "extremely" (4), where higher scores reflect greater impact on day to day life |
Baseline up to 30 months
|
|
Number of participants with Adverse events and Serious adverse events(SAE) [Core Part]
Délai: Baseline up to 30 months
|
Adverse events and SAEs including clinically significant, laboratory data, vital signs, electrocardiogram (ECG), Columbia Suicide Severity Rating |
Baseline up to 30 months
|
|
Pharmacokinetics of remibrutinib [Core Part]
Délai: Month 1, Month 6
|
Blood concentrations of remibrutinib |
Month 1, Month 6
|
|
Number of participants with Adverse events and Serious adverse events (SAE) [Extension Part]
Délai: Day 1 Extension up to 5 years
|
Adverse events and SAEs including clinically significant, laboratory data, vital signs, electrocardiogram (ECG), Columbia Suicide Severity Rating |
Day 1 Extension up to 5 years
|
|
Annualized relapse rate (ARR) of confirmed relapses [Extension Part]
Délai: Day 1 Extension up to 5 years
|
ARR is the average number of confirmed MS relapses in a year |
Day 1 Extension up to 5 years
|
|
Annualized rate of new or enlarging T2 lesion [Extension Part]
Délai: Day 1 Extension up to 5 years
|
Number of new/newly enlarged T2 lesions per year |
Day 1 Extension up to 5 years
|
|
Time to 6-month confirmed disability progression (6mCDP) on EDSS [Extension Part]
Délai: Day 1 Extension up to 5 years
|
Time to 6-month confirmed disability progression (6mCDP) is defined as an increase in Expanded Disability Status Scale (EDSS) which is sustained for at least 6 months |
Day 1 Extension up to 5 years
|
|
Change from baseline in the Symbol Digit Modalities Test (SDMT) [Extension Part]
Délai: Day 1 Extension up to 5 years
|
Symbol Digit Modalities Test (SDMT), an array of symbols paired with empty spaces, measures processing in speed; participants verbally match the number for each symbol as rapidly as possible. The score is the number of correctly coded items in 90 seconds. Higher scores indicate improvement. Lower scores indicate worsening |
Day 1 Extension up to 5 years
|
|
Neurofilament light chain (NfL) [Extension Part]
Délai: Day 1 Extension up to 5 years
|
Neurofilament light chain (NfL) concentration in serum |
Day 1 Extension up to 5 years
|
|
Change from baseline in Multiple Sclerosis Impact Scale (MSIS-29) [Extension Part]
Délai: Day 1 Extension up to 5 years
|
29-item, self-administered questionnaire that includes 2 domains, physical and psychological. Responses are captured on a 4-point scale ranging from "not at all" (1) to "extremely" (4), where higher scores reflect greater impact on day to day life |
Day 1 Extension up to 5 years
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- CLOU064C12302
- 2023-509372-41-00 (Identificateur de registre: EU CTIS)
- 2023 (Subvention/contrat des NIH des États-Unis)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .